Navigation Links
Evidence-Based Cardiology, Second Edition

ProductsEvidence-Based Cardiology, Second Edition
Company Skyscape, Inc.
Item Evidence-Based Cardiology, Second Edition
Features 
  • Easy-to-navigate screens provide succinct information on the pathophysiology of each disease and the guideline-recommended diagnostic tests and treatments
  • With Skyscape's patented smARTlink™ technology, EBCard™ can easily cross-index with other titles from Skyscape
Description This PDA reference is an indispensable decision-making aid for all physicians who treat cardiovascular disease. It provides instant access to the latest American College of Cardiology and American Heart Association guidelines and the most current clinical trial data that support or refute clinical interventions.
Info Skyscape, Inc.
Customer Service: 508-460-6500

Related medicine products :

1. Greenberg Secondary Bar
2. USA Series DUR-8 Elite Durable Flexible Ureteroscope System with Primary and Secondary Deflection
3. Antimicrobial Susceptibility-AFB/Mycobacterium tuberculosis Secondary Panel
4. HRR 4th Edition Test with Spanish and English Instructions
5. HRR 4th Edition Pseudoisochromatic Test - English Instruction Version
6. MiniSpin plus Special Limited Edition Personal Micro Centrifuge
7. Harrisons Manual of Medicine, 15th Edition
8. Essentials of Diagnosis and Treatment 2nd Edition for PDA
9. Daviss Drug Guide for Nurses, 9th Edition for PDA
10. Schwartz Principles of Surgery PDA Edition
11. 2005 Edition of Geriatrics At Your Fingertips (PDA Version)
Other Medicine News:Health News:eDiets.com(R) Announces Q3 2008 Results 2Health News:eDiets.com(R) Announces Q3 2008 Results 3Health News:eDiets.com(R) Announces Q3 2008 Results 4Health News:eDiets.com(R) Announces Q3 2008 Results 5Health News:eDiets.com(R) Announces Q3 2008 Results 6Health News:eDiets.com(R) Announces Q3 2008 Results 7Health News:Pelvic Inflammation Puts Girls at Risk for Repeat STIs 2Health News:Watson Announces the NDA for a 6-Month Formulation of TRELSTAR(R) Accepted for Filing by FDA for the Treatment of Advanced Prostate Cancer 2Health News:Watson Announces the NDA for a 6-Month Formulation of TRELSTAR(R) Accepted for Filing by FDA for the Treatment of Advanced Prostate Cancer 3Health News:Watson Announces the NDA for a 6-Month Formulation of TRELSTAR(R) Accepted for Filing by FDA for the Treatment of Advanced Prostate Cancer 4Health News:Top NY Court Blinks in 'First Department' WPP Discrimination Power Play 2Health News:Top NY Court Blinks in 'First Department' WPP Discrimination Power Play 3Health News:Top NY Court Blinks in 'First Department' WPP Discrimination Power Play 4Health News:Top NY Court Blinks in 'First Department' WPP Discrimination Power Play 5Health News:Leading Scientists From Around the World Headed to Kansas for Symposium on Combating Deadly Infectious Diseases 2Health News: FDA Approves Low-dose Regimen of PREMARIN Vaginal Cream to Treat Moderate to Severe Postmenopausal Dyspareunia – Painful Sexual Intercourse : Agency Grants New Indication for Bothersome Vaginal Symptom Associated with Menopause 2Health News: FDA Approves Low-dose Regimen of PREMARIN Vaginal Cream to Treat Moderate to Severe Postmenopausal Dyspareunia – Painful Sexual Intercourse : Agency Grants New Indication for Bothersome Vaginal Symptom Associated with Menopause 3Health News: FDA Approves Low-dose Regimen of PREMARIN Vaginal Cream to Treat Moderate to Severe Postmenopausal Dyspareunia – Painful Sexual Intercourse : Agency Grants New Indication for Bothersome Vaginal Symptom Associated with Menopause 4
Breaking Medicine Technology:Nearly 100 HIV/AIDS Drugs and Vaccines in Development Pipeline 2New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 2New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 3New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 2China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 3China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 5China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 6China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 7China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 8Preventing toxic shock syndrome and other severe diseases 53247 1Got zinc 3F New zinc research suggests novel therapeutic targets 9433 1Got zinc 3F New zinc research suggests novel therapeutic targets 9433 2Recovery act funded research projects aid communities across the country 9428 1